Cargando…

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma

SIMPLE SUMMARY: Cholangiocarcinoma constitutes around 3% of gastrointestinal cancers, and mortality from this cancer has been rising in the recent decades. Many cases of cholangiocarcinoma are unfortunately discovered in their advanced stages which cannot be treated with surgical resection alone. Ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Su Min, Esmail, Abdullah, Raza, Ali, Dacha, Sunil, Abdelrahim, Maen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179455/ https://www.ncbi.nlm.nih.gov/pubmed/35681621 http://dx.doi.org/10.3390/cancers14112641

Ejemplares similares

Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)

Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
por: Choi, Ha Yeong, et al.
Publicado: (2023)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
por: Krakauer, Teresa
Publicado: (2017)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
por: Fisher, Jacob P., et al.
Publicado: (2021)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Utility of Cell-Free DNA Detection in Transplant Oncology
por: Reddy, Tejaswini, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
por: Benedetto Tiz, Davide, et al.
Publicado: (2022)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
por: Spiegel, Lauren L., et al.
Publicado: (2020)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
por: Shabir, Ghulam, et al.
Publicado: (2023)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Why Are There So Few FDA-Approved Therapeutics for Wound Healing?
por: Chen, Mei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9v4agv6avp07ki5gftvi5uf43u